GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannabis Bioscience International Holdings Inc (OTCPK:CBIH) » Definitions » Net Income Including Noncontrolling Interests

Cannabis Bioscience International Holdings (Cannabis Bioscience International Holdings) Net Income Including Noncontrolling Interests : $-0.31 Mil (TTM As of Nov. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Cannabis Bioscience International Holdings Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Cannabis Bioscience International Holdings's Net Income Including Noncontrolling Interests for the six months ended in Nov. 2023 was $-0.31 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Nov. 2023 was $-0.31 Mil.


Cannabis Bioscience International Holdings Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Cannabis Bioscience International Holdings's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cannabis Bioscience International Holdings Net Income Including Noncontrolling Interests Chart

Cannabis Bioscience International Holdings Annual Data
Trend Dec06 Dec07 May09 May10 May11
Net Income Including Noncontrolling Interests
-0.02 -0.06 11.07 -12.59 11.17

Cannabis Bioscience International Holdings Semi-Annual Data
Dec06 Jun07 Dec07 Jun08 May09 Nov09 May10 Nov10 May11 Nov11 Nov22 Nov23
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.39 1.78 5.32 -0.43 -0.31

Cannabis Bioscience International Holdings Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Nov. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cannabis Bioscience International Holdings Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Cannabis Bioscience International Holdings's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.


Cannabis Bioscience International Holdings (Cannabis Bioscience International Holdings) Business Description

Traded in Other Exchanges
N/A
Address
6201 Bonhomme Road, Suite 466S, Houston, TX, USA, 77036
Cannabis Bioscience International Holdings Inc is engaged in providing educational systems relating to cannabis and services in therapeutic areas. of clinical trials and services relating to sleep disorders through its sleep center in Houston, Texas. The Company generates revenue from multiple streams, namely, clinical trials, consulting fees, video courses, seminars, royalties, and merchandise sales. The company generates the majority of its revenue from clinical trials.